Trump Imposes New Pharma, Metal Tariffs
Analysis based on 23 articles · First reported Apr 02, 2026 · Last updated Apr 03, 2026
The new tariffs on pharmaceuticals could increase healthcare costs for American families and jeopardize U.S. investments in the biopharmaceutical sector. Adjustments to metals tariffs may raise prices for consumers and add pressure to manufacturing, construction, and energy industries, although the Steel Manufacturers Association views the changes as beneficial for the American steel industry.
President Donald Trump has ordered new tariffs on certain branded pharmaceutical imports and adjusted existing duties on steel, aluminum, and copper. Foreign manufacturers of patented drugs must agree to cut prescription-drug prices and commit to moving production to the United States to avoid 100% tariffs, with some countries like the European Union, Japan, South Korea, and Switzerland having tariffs capped at 15%, and the United Kingdom securing a zero-tariff deal for three years. For metals, the 50% duty on commodity imports remains but will be applied to the U.S. sales price. Tariffs on many derivative products made with steel, aluminum, and copper have been halved to 25%, and eliminated for products with less than 15% metal content. These changes follow the United States — Supreme Court of the United States striking down previous broad global tariffs and are aimed at rebuilding duties and simplifying the tariff regime. The Pharmaceutical Research and Manufacturers of America and the United States Chamber of Commerce have criticized the new tariffs, warning of increased costs and negative impacts on various industries, while the Steel Manufacturers Association has praised the metals tariff adjustments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard